Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,059 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatobiliary Disorders Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

NCT06974565
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Quinidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04929483
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
BIO89-100, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Phase 2 Interventional

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

NCT00228592
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepeX-B, Hepatitis B Immune Globulin (HBIg)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04505436
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HM15211, Placebo of HM15211
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
48
States / cities
Huntsville, Alabama • Chandler, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Phase 1Phase 2 Interventional

Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

NCT03511365
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018, Interleukin-17 MeSH Descriptor Data 2018
Interventions
Probiotic Formulation VSL#3
Biological
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 26, 2026, 8:27 AM EDT
Completed No phase listed Observational

Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference

NCT04389593
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

NCT05680233
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions
OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
Drug
Lead sponsor
Oasis Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention

NCT07010315
View directory record Official record
Conditions
Liver Cancer
Interventions
Cognitive Testing, Usability Testing
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis

NCT00736840
View directory record Official record
Conditions
Chronic Liver Disease
Interventions
c13 methacetin solution with breath analyzer
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Detroit, Michigan • Cleveland, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children

NCT02383485
View directory record Official record
Conditions
Overweight and Obesity, Non-alcoholic Fatty Liver Disease
Interventions
Exercise, After-school program
Behavioral
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 11 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Phase 2 Interventional Results available

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02787304
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Coronado, California • Fresno, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 26, 2026, 8:27 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

NCT06354491
View directory record Official record
Conditions
NAFLD, NASH
Interventions
Magnetic Resonance Imaging (MRI), Ultrasound (US)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
10 Years to 14 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 26, 2026, 8:27 AM EDT
Withdrawn Early Phase 1 Interventional

Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation

NCT03468140
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Eculizumab, No intervention
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
El Cajon, California • Murrieta, California • Rialto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

NCT03950882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
PXL770, Placebo
Drug
Lead sponsor
Poxel SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 26, 2026, 8:27 AM EDT
Completed No phase listed Observational

Genetics of Fatty Liver Disease in Children

NCT01966627
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
ogtt, genotyping, abdominal and liver magnetic resonance imaging, stool sample, liver biopsy
Other
Lead sponsor
Yale University
Other
Eligibility
7 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 26, 2026, 8:27 AM EDT
Active, not recruiting No phase listed Observational

Liver Disease in Urea Cycle Disorders

NCT04612764
View directory record Official record
Conditions
Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency, Citrullinemia 1, ARGI Deficiency, ASL Deficiency, Argininosuccinic Aciduria, ASS Deficiency, Hyperargininemia
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Not listed Phase 1 Interventional

Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC

NCT03838250
View directory record Official record
Conditions
Alcoholic Liver Cirrhosis
Interventions
Cellgram™ (Bone marrow-derived MSCs)
Biological
Lead sponsor
Pharmicell Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

NCT03432260
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

NCT00826020
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis
Interventions
Omegaven™
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Not applicable Interventional Results available

Polycystic Liver Disease in Kidney Transplant

NCT00934791
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
Tacrolimus, Sirolimus, Mycophenolate Mofetil, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish Oil Supplementation, Placebo Supplementation
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

NCT00031343
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 8:27 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

NCT04702490
View directory record Official record
Conditions
NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2, Diabetes, Fatty Liver, Fatty Liver, Nonalcoholic, NAFLD
Interventions
MET409 Active, MET409 Placebo, Empagliflozin
Drug
Lead sponsor
Metacrine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Fort Myers, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 26, 2026, 8:27 AM EDT